Loading stock data…
$319.64-0.37 (-0.12%)
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally.
Penumbra, Inc. in the Healthcare sector is trading at $319.64 with a market capitalization of $12.9B. Wall Street consensus targets $362.54 (13 analysts), implying a +13.4% move over the next 12 months. The stock is currently 12% below its 52-week high of $362.41, remaining 2.2% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $390.05M↑ | $374.76M↓ | $385.38M↑ | $354.69M↑ | $339.45M |
| Gross Profit | $264.94M↑ | $253.41M↓ | $262.13M↑ | $240.42M↑ | $224.01M |
| Operating Income | $41.04M↑ | $38.23M↓ | $59.23M↑ | $48.84M↑ | $40.83M |
| Net Income | $34.81M↑ | $32.58M↓ | $47.34M↑ | $45.85M↑ | $45.27M |
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the In...